高剂量胃复安和高剂量阿立必利联合劳拉西泮对接受癌症化疗患者的止吐活性。一项前瞻性、随机、双盲研究。
The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind study.
作者信息
Molino A, Guglielmo L, Azzolini M E, Biondani P, Capelli M C, Grandinetti A, Griso C, Martinelli G, Martini N, Zanotti R
机构信息
Cattedra di Oncologia Medica, Università di Verona, Italia.
出版信息
Oncology. 1991;48(2):111-5. doi: 10.1159/000226907.
The antiemetic efficacy of metoclopramide and lorazepam (MTC + L) versus alizapride and lorazepam (ALZ + L) was compared in 100 patients receiving chemotherapy, in a prospective randomized double-blind study. In highly emetogenic (HE) regimen (including platinum) patients received MTC 1 mg/kg or ALZ 3 mg/kg x 4 doses, and lorazepam 2.5 mg 30 min before therapy. In moderately emetogenic (ME) regimen patients received MTC 0.5 mg/kg or ALZ 1.5 mg kg x 3 doses, and lorazepam 2.5 mg 30 min before therapy. In both HE and ME regimen groups there was no statistically significant difference between MTC + L and ALZ + L treatments as regards the number of vomiting episodes, the duration of emesis and nausea, the intensity of nausea and side effects, but a statistically significant difference between treatments was found in the HE group where MTC-L was superior to ALZ + L in obtaining complete protection from vomiting (37 vs 11%, p = 0.05). No significant difference in side effects was observed.
在一项前瞻性随机双盲研究中，对100例接受化疗的患者比较了甲氧氯普胺与劳拉西泮（MTC + L）和阿立必利与劳拉西泮（ALZ + L）的止吐效果。在高度致吐（HE）方案（包括铂类）中，患者接受1 mg/kg的MTC或3 mg/kg的ALZ，共4剂，并在治疗前30分钟给予2.5 mg劳拉西泮。在中度致吐（ME）方案中，患者接受0.5 mg/kg的MTC或1.5 mg/kg的ALZ，共3剂，并在治疗前30分钟给予2.5 mg劳拉西泮。在HE和ME方案组中，MTC + L和ALZ + L治疗在呕吐发作次数、呕吐和恶心持续时间、恶心强度和副作用方面均无统计学显著差异，但在HE组中发现治疗之间存在统计学显著差异，其中MTC-L在完全预防呕吐方面优于ALZ + L（37%对11%，p = 0.05）。未观察到副作用有显著差异。
Zotero 插件